Study of Minimally-invasive Ablative Renal Therapies (SMART) Registry

NCT05210933 | Suspended

• 1 other identifier: HREBA.CC-20-0432
• Study Type: observational
• Target: 750
• Locations: 1 country
• Sites: 2

Brief Summary

Multi-center prospective cohort study examining curative intent renal cryotherapy and radiofrequency ablation for small renal mass treatment in patients who are poor candidates for surgical resection, We will capture clinical, radiological, and pathological data as well as resource utilization (ex: time in hospital, ER visits), complications, and long-term functional and oncological outcomes. The investigators will also be biobanking blood and urine samples from participants for biological studies in the lab.

Conditions

Renal Cancer

Keywords

renal cancer; cryoablation; small renal mass

Outcome Measures

Primary Outcomes (1)

• kidney cancer disease-specific survival

  5 years

Secondary Outcomes (4)

• Overall survival

  5 years

• Glomerular Filtration Rate GFR (mL/min/1.73m2)

  5 years

• Serum Creatinine (umol/L)

  5 years

• Progression-free survival

  5 years

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Adult Albertans with a diagnosis of kidney cancer

You may qualify if:

• Adults with prior kidney tumor diagnosis;
• Willing to permit provincial agencies (e.g Alberta Health Services, Alberta Health, Netcare, Service Alberta) to disclose health-related information to study;
• Canadian and Albertan residents;
• Signed informed consent.

You may not qualify if:

• Unwilling to participate in the study;
• Unavailable for standard clinical urological care or follow-up in Alberta

Sponsors & Collaborators

• University of Alberta: lead

Study Sites (2)

University of Calgary

Calgary, Alberta, Canada

Location

University of Alberta

Edmonton, Alberta, Canada

Location

Related Publications (2)

• Kassouf W, Monteiro LL, Drachenberg DE, Fairey AS, Finelli A, Kapoor A, Lattouf JB, Leveridge MJ, Power NE, Pouliot F, Rendon RA, Sabbagh R, So AI, Tanguay S, Breau RH. Canadian Urological Association guideline for followup of patients after treatment of non-metastatic renal cell carcinoma. Can Urol Assoc J. 2018 Aug;12(8):231-238. doi: 10.5489/cuaj.5462. Epub 2018 May 31. No abstract available.

  PMID: 30139427 BACKGROUND

• Thompson RH, Atwell T, Schmit G, Lohse CM, Kurup AN, Weisbrod A, Psutka SP, Stewart SB, Callstrom MR, Cheville JC, Boorjian SA, Leibovich BC. Comparison of partial nephrectomy and percutaneous ablation for cT1 renal masses. Eur Urol. 2015 Feb;67(2):252-9. doi: 10.1016/j.eururo.2014.07.021. Epub 2014 Aug 6.

  PMID: 25108580 BACKGROUND

Biospecimen

Retention: SAMPLES WITH DNA

Blood and urine samples will be collected at baseline (i.e. study entry), and once after treatment is complete.

MeSH Terms

Conditions

Kidney Neoplasms

Condition Hierarchy (Ancestors)

Urologic Neoplasms; Urogenital Neoplasms; Neoplasms by Site; Neoplasms; Female Urogenital Diseases; Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Kidney Diseases; Urologic Diseases; Male Urogenital Diseases

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 10 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 13, 2021
• First Posted: January 27, 2022
• Study Start: April 1, 2022
• Primary Completion (Estimated): December 31, 2026
• Study Completion (Estimated): December 31, 2031
• Last Updated: April 13, 2026

Record last verified: 2026-04

Locations

CA (2)